- NanoString Technologies (NASDAQ:NSTG) and Riken Genesis, a subsidiary of Sysmex Corporation have entered into a partnership to introduce nCounter-based diagnostic assays in Japan.
- Under this agreement, NanoString and Riken will collaborate to register, obtain reimbursement and commercialize companion diagnostic assays in Japan, including NanoString’s Lymphoma Subtyping Test which will be marketed as the nCounter Dx LymphMark assay.
- Financial terms are not disclosed.
- LymphMark is a 20-gene signature that classifies cell-of-origin subtypes of Diffuse Large B-cell Lymphoma tumors.